Kalaris Therapeutics Inc
KLRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $45,677 | $12,132 | $12,132 | $24,894 |
| - Cash | $118,289 | $3,169 | $3,059 | $201,661 |
| + Debt | $0 | $0 | $3,253 | $30,066 |
| Enterprise Value | -$72,612 | $8,963 | $12,326 | -$146,701 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | -$1,117 |
| % Margin | – | – | – | – |
| EBITDA | -$58,769 | -$14,012 | -$15,250 | -$169,838 |
| % Margin | – | – | – | – |
| Net Income | -$58,769 | -$14,699 | -$15,485 | -$171,962 |
| % Margin | – | – | – | – |
| EPS Diluted | -11.73 | -42.089 | -50.621 | -63 |
| % Growth | 72.1% | 16.9% | 19.6% | – |
| Operating Cash Flow | -$67,705 | -$14,132 | -$9,779 | -$106,319 |
| Capital Expenditures | $0 | $0 | $0 | -$26 |
| Free Cash Flow | -$67,705 | -$14,132 | -$9,779 | -$106,345 |